Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal palivizumab in an RSV human challenge model
2020-004137-21Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of palivizumab in respiratory syncytial virus disease (RSV), sponsored by University Medical Center Utrecht. Primary endpoint: Productive RSV infection rate. Started Aug 2021; status: completed.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2020-004137-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004137-21.